Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Pzena Investment Management LLC filed Amendment No. 1 to its Schedule 13G on 15 July 2025, disclosing beneficial ownership of 39,708,226 shares of Baxter International Inc. (BAX) common stock, equal to 7.7 % of the outstanding class as of 30 June 2025.
The New York–based investment adviser reports sole voting power over 33,062,441 shares and sole dispositive power over the full 39.7 million shares; no shares are subject to shared voting/dispositive control. The filing states that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of Baxter.
This disclosure signals that a well-known value-oriented institutional investor maintains a sizable position above the 5 % threshold, information that may influence perceptions of Baxter’s shareholder base and potential governance dynamics. However, the filing contains no operational or financial performance data and does not indicate any activist intent.